Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

SML0936

Sigma-Aldrich

Teriflunomide

≥98% (HPLC)

Sinônimo(s):

(Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide, A 1726, A77-1726, A771726, Flucyamide, HMR 1726, N-(4-Trifluoromethylphenyl)-2-cyano-3-hydroxycrotoamide, SU 20

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C12H9F3N2O2
Número CAS:
Peso molecular:
270.21
Código UNSPSC:
12352200
NACRES:
NA.77

Nível de qualidade

Ensaio

≥98% (HPLC)

Formulário

powder

cor

white to beige

solubilidade

DMSO: 5 mg/mL, clear (warmed)

temperatura de armazenamento

−20°C

InChI

1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-

chave InChI

UTNUDOFZCWSZMS-YFHOEESVSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Aplicação

Teriflunomide has been used as a dihydroorotate dehydrogenase (DHODH) inhibitor.

Ações bioquímicas/fisiológicas

Teriflunomide is an orally available anti-inflammatory immunomodulator. It blocks the activity of dihydroorotate dehydrogenase, preventing pyrimidine synthesis and T and B cell proliferation and function. Teriflunomide has been used to treat rheumatoid arthritis and was recently approved for multiple sclerosis.

Pictogramas

Exclamation mark

Palavra indicadora

Warning

Frases de perigo

Declarações de precaução

Classificações de perigo

Acute Tox. 4 Oral

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia.
Sykes D B, et al.
Cell, 167(1), 171-186 (2016)
Deepti Mathur et al.
Cancer discovery, 7(4), 380-390 (2017-03-04)
Metabolic changes induced by oncogenic drivers of cancer contribute to tumor growth and are attractive targets for cancer treatment. Here, we found that increased growth of
Mieradilijiang Abudupataer et al.
eLife, 10 (2021-09-07)
Bicuspid aortic valve (BAV) is the most common congenital cardiovascular disease in general population and is frequently associated with the development of thoracic aortic aneurysm (TAA). There is no effective strategy to intervene with TAA progression due to an incomplete
Andrea Bilger et al.
Oncotarget, 8(27), 44266-44280 (2017-06-03)
EBV infection causes mononucleosis and is associated with specific subsets of B cell lymphomas. Immunosuppressed patients such as organ transplant recipients are particularly susceptible to EBV-induced lymphoproliferative disease (LPD), which can be fatal. Leflunomide (a drug used to treat rheumatoid
Zhen-Guo Ma et al.
Clinical science (London, England : 1979), 132(6), 685-699 (2018-03-16)
T-cell infiltration and the subsequent increased intracardial chronic inflammation play crucial roles in the development of cardiac hypertrophy and heart failure (HF). A77 1726, the active metabolite of leflunomide, has been reported to have powerful anti-inflammatory and T cell-inhibiting properties.

Conteúdo relacionado

We offer agonists, antagonists, modulators and other bioactive small molecules for immune system signaling target identification and validation, as well as a variety of antibiotics, antivirals, and antifungals.

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica